The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa-Reference-Cited by-同舟云学术

The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa

Published:2013-02-15 Issue:2 Volume:8 Page:e54435
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Schneider Karen,Nwizu Chidi,Kaplan Richard,Anderson Jonathan,Wilson David P.,Emery Sean,Cooper David A.,Boyd Mark A.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. Joint United Nations Programme on AIDS (UNAIDS). (2011) Global HIV/AIDS Response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. Geneva: UNAIDS.

2. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared;O Keiser;PLoS Med,2008

3. Cahn P (2008) WHO Expert Consultation on ART failure definitions in the context of the public health approach. 26–27 February 2008 – Montreux, Switzerland.

4. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy;MC Hosseinipour;AIDS,2009

5. Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine;W Manosuthi;AIDS Res Hum Retroviruses,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa;PharmacoEconomics - Open;2019-07-04

2. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study;The Lancet;2013-06